BEAM - BEAM

Beam Therapeutics (NASDAQ:BEAM) 주식

Beam Therapeutics

Beam Inc.

NYSE

Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.

Equities

News

Markets

ETFs

ADPT

ARKF

ARKG

ARKK

BEAM

MELI

금요일에 캐시 우드가 이끄는 안크 인베스트가 빔 테라퓨틱스(NASDAQ:BEAM), 누 홀딩스(NYSE:NU), 메르카도리브레(NASDAQ:MELI), 그리고 어댑티브 바이오테크놀로지스(NASDAQ:ADPT)와 관련하여 큰 거래를 했다.

아크 인베스트, 빔 테라퓨틱스와 누 홀딩스에 투자 확대: 메르카도리브레와 어댑티브 매도

Tech

ARKW

IBTA

IRDM

ROKU

TWST

금요일에 캐시 우드가 이끄는 아크 인베스트가 이리듐 커뮤니케이션스(NASDAQ:IRDM), 트위스트 바이오사이언스(NASDAQ:TWST), 페이저듀티(NYSE:PD), 빔 테라퓨틱스(NASDAQ:BEAM), 로쿠(NASDAQ:ROKU), 그리고 아이보타(NASDAQ:IBTA)와 같은 주식들에 대해 중요한 거래를 진행했다.

아크 인베스트의 금요일 거래, 이리듐과 트위스트 바이오사이언스를 매수, 로쿠를 매도

Biotech

Health Care

CDNA

CRSP

NTLA

RXRX

VCYT

아크 인베스트의 CEO인 캐시 우드는 인공지능, 유전자 염기서열(시퀀싱) 분석, 유전자 편집 기술의 교차점에서 전례 없는 잠재력을 발견하고 바이오 분야에 투자를 강화하고 있다.

캐시 우드, 바이오 분야에서 4천억 달러 기회 전망

Beam Therapeutics Inc

BEAM - United States Dollar

BEAM COMM HLDGS LTD by BEAM COMMUNICATIONS HLDGS LTD.

Beam Global

Beamr Imaging Ltd

BEAMZ INTERACTIVE INC by Beamz Interactive Inc

Beamz Interactive Inc

On Friday, Cathie Wood-led Ark Invest made significant trades involving Beam Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>), Nu Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NU#NYSE">NU</a>), MercadoLibre Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>), and Adaptive Biotechnologies Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>).
The BEAM Trade
Ark Invest, through its ARK Genomic Revolution ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>) and ARK Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>), bought a total of 24,640 shares of Beam Therapeutics.
This comes after the firm&#8217;s <a href="https://www.benzinga.com/25/02/43755344/cathie-woods-ark-invest-loads-up-on-iridium-twist-bioscience-offloads-roku-here-are-key-ark-trades-this-friday">previous acquisition</a> of Beam Therapeutics shares just a week prior. The value of this trade, calculated from the latest closing price is nearly $750,000.
The NU Trade
Ark Invest, through its ARK Fintech Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKF#NYSE">ARKF</a>), bought 162,143 shares of Nu Holdings Ltd. This marks a significant investment in the fintech company, reflecting Ark&#8217;s strategic positioning in the dynamic tech sector.
The value of this trade, calculated from the latest closing price is over $1.75 million.
The MELI and ADPT Trades
On the same day, Ark Invest also sold shares of MercadoLibre Inc and Adaptive Biotechnologies Corp. Through its ARK Fintech Innovation ETF, Ark sold 347 shares of MercadoLibre.
Meanwhile, through its ARK Genomic Revolution ETF, Ark offloaded 8,129 shares of Adaptive Biotechnologies.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43900360/bill-gates-has-a-warning-for-the-next-generation-says-be-very-afraid-of-these-4-issues">Bill Gates Has A Warning For The Next Generation, Says Be ‘Very Afraid&#8217; Of These 4 Issues</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Ark Invest

Cathie Wood's Ark Invest Loads Up On Beam Therapeutics, Nu Holdings: Offloads MercadoLibre, Adaptive Biotechnologies

On Friday,&nbsp;Cathie Wood-led&nbsp;Ark Invest&nbsp;made significant trades involving stocks such as&nbsp;Iridium Communications Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRDM#NASDAQ">IRDM</a>),&nbsp;Twist Bioscience Corp&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>),&nbsp;PagerDuty Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PD#NYSE">PD</a>),&nbsp;Beam Therapeutics Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>),&nbsp;Roku Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>), and&nbsp;Ibotta Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBTA#NASDAQ">IBTA</a>).
The IRDM Trade
Ark Invest, through its ARK Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>), bought 86,666 shares of Iridium Communications.
The closing price of IRDM on Friday was $31.63, making the total value of this trade approximately $2.74 million. This move comes amidst a slight decline in IRDM&#8217;s stock price, with a 1.13% change on Friday.
The TWST Trade
Ark Invest also purchased 36,806 shares of Twist Bioscience Corp through ARKK.
With a closing price of $47.59, the total value of this trade amounts to approximately $1.75 million. TWST's stock price surged by more than 1.5% on Friday.
The PD Trade
Ark Invest bought 35,546 shares of PagerDuty Inc through ARKK and an additional 10,215 shares through its ARK Next Generation Internet ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>).
With PD&#8217;s closing price on Friday at $19.3, the total value of this trade is approximately $882,000.
Other Key Trades:
<ul>
<li>Ark Invest bought 24,250 shares of Ibotta Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBTA#NASDAQ">IBTA</a>) through its ARK Fintech Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKF#NYSE">ARKF</a>).</li>
<li>Ark Invest bought 1,916 shares of Beam Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) through its ARK Genomic Revolution ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#NYSE">ARKG</a>) and ARK Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>).</li>
<li>Ark Invest sold 46,810 shares of Roku Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) through its ARKK and ARK Next Generation Internet ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>).</li>
</ul>
These trades reflect Ark Invest&#8217;s strategic decisions in the face of the dynamic tech sector&#8217;s performance.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43755136/bill-gates-wanted-a-friend-to-take-charge-of-microsoft-due-to-regret-over-leaving-harvard-but-heres-why-he-panick">Bill Gates Wanted A Friend To &#8216;Take Charge&#8217; Of Microsoft Due To Regret Over Leaving Harvard, But Here&#8217;s Why He Panicked And Dropped Out</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image via Ark Invest

Cathie Wood's Ark Invest Loads Up On Iridium, Twist Bioscience, Offloads Roku: Here Are Key Ark Trades This Friday

U.S. stocks were mostly lower, with the Dow Jones falling around 100 points on Friday.
Shares of The Goodyear Tire &amp; Rubber Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GT#NASDAQ">GT</a>) rose sharply during Friday's session after the company reported better-than-expected <a href="https://www.benzinga.com/quote/GT/analyst-ratings">quarterly financial results</a>.
Goodyear Tire &amp; Rubber reported quarterly earnings of 39 cents per share which beat the analyst consensus estimate of 31 cents per share. The company reported quarterly sales of $4.95 billion which beat the analyst consensus estimate of $4.87 billion.
Goodyear Tire &amp; Rubber shares jumped 19.4% to $9.76 on Friday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>WeRide Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRD#NASDAQ">WRD</a>) shares jumped 97.7% to $33.94 after Nvidia disclosed a stake of 1.74 million shares in a 13F filing.</li>
<li>Nu Skin Enterprises, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUS#NYSE">NUS</a>) gained 34.6% to $8.65 following upbeat quarterly earnings.</li>
<li>Udemy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UDMY#NASDAQ">UDMY</a>) gained 23.7% to $9.67 after the company reported fourth-quarter earnings and revenue above estimates.</li>
<li>Pacific Biosciences of California, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) rose 20.9% to $1.7900 following upbeat quarterly earnings.</li>
<li>Kingsoft Cloud Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>) gained 20.3% to $20.86.</li>
<li>Personalis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNL#NASDAQ">PSNL</a>) gained 17.2% to $5.85.</li>
<li>TreeHouse Foods, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THS#NYSE">THS</a>) gained 17% to $38.90 following fourth-quarter results.</li>
<li>Pony AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>) climbed 16% to $17.25.</li>
<li>Airbnb, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) gained 15.8% to $163.43 following a quarterly revenue beat. Multiple analysts upgraded the stock following the report.</li>
<li>Roku, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) rose 15.2% to $100.00 following better-than-expected quarterly financial results.</li>
<li>Beam Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) gained 14.8% to $32.85.</li>
<li>CAE Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAE#NYSE">CAE</a>) rose 14.7% to $26.98 after the company reported a year-over-year increase in third-quarter financial results.</li>
<li>DraftKings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) gained 13.3% to $52.62 after the company reported better-than-expected quarterly adjusted EPS results and raised its FY25 revenue guidance.</li>
<li>West Pharmaceutical Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) rose 11.2% to $221.56.</li>
<li>Pilgrim&#8217;s Pride Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPC#NASDAQ">PPC</a>) gained 9.6% to $57.07.</li>
<li>Tencent Music Entertainment Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TME#NYSE">TME</a>) rose 5.3% to $13.43</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/02/43692962/top-3-consumer-stocks-you-may-want-to-dump-in-february">Top 3 Consumer Stocks You May Want To Dump In February</a></li>
</ul>

Intraday Update

Movers

Trading Ideas

ABNB

DKNG

PACB

PONY

PSNL

UDMY

Goodyear Tire & Rubber Posts Upbeat Results, Joins Nu Skin, Pacific Biosciences of California, Airbnb, Roku And Other Big Stocks Moving Higher On Friday

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Beam Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) with a Buy and maintains $80 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target

Beam Therapeutics's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NYSE">BEAM</a>) short percent of float has risen 9.09% since its last report. The company recently reported that it has 10.79 million shares sold short, which is 17.04% of all regular shares that are available for trading. Based on its trading volume, it would take traders 7.37 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Beam Therapeutics Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738344611_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Beam Therapeutics has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Beam Therapeutics's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Beam Therapeutics's peer group average for short interest as a percentage of float is 13.00%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

(BEAM) - Analyzing Beam Therapeutics's Short Interest

In the preceding three months, 4 analysts have released ratings for Beam Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>), presenting a wide array of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Beam Therapeutics and provided 12-month price targets. The average target is $55.75, accompanied by a high estimate of $80.00 and a low estimate of $24.00. This current average reflects an increase of 4.21% from the previous average price target of $53.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1738180813_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A clear picture of Beam Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$24.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Rick Bienkowski</td>
<td>Leerink Partners</td>
<td>Raises</td>
<td>Outperform</td>
<td>$39.00</td>
<td>$27.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Beam Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Beam Therapeutics compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Beam Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Beam Therapeutics's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BEAM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Beam Therapeutics analyst ratings.</a>
<h2>Unveiling the Story Behind Beam Therapeutics</h2>
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.
<h3>Beam Therapeutics: Delving into Financials</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Beam Therapeutics's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately -17.01%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -677.47%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Beam Therapeutics's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -11.75%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -7.95%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Beam Therapeutics's debt-to-equity ratio is below the industry average. With a ratio of 0.2, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: What Are They?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying Beam Therapeutics: Insights From 4 Analyst Reviews

Cantor Fitzgerald analyst Rick Bienkowski upgrades Beam Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) from Neutral to Overweight.

Upgrades

Cantor Fitzgerald Upgrades Beam Therapeutics to Overweight

Beam Therapeutics To Encore Data From BEACON Phase 1/2 Clinical Trial Of BEAM-101 In Sickle Cell Disease At Tandem Meetings Of ASTCT And CIBMTR

Beam Therapeutics Expects Cash Runway To Support Operating Plans Into 2027, Now Inclusive Of Commercial Readiness Activities For BEAM-101

On Saturday, Beam Therapeutics Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) revealed new safety and efficacy data from its BEACON Phase 1/2 trial of BEAM-101 in patients with sickle cell disease (SCD) with severe <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42378289/beam-therapeutics-announces-new-data-from-beacon-phase-12-clinical-trial-of-beam-101-in-sickle-cel" rel="noreferrer noopener">vaso-occlusive crises (VOCs)</a>.
The data were featured at the American Society of Hematology (ASH) Annual Meeting and Exposition.
Consistent with Beam&#8217;s&nbsp;previously announced&nbsp;data, updated data from seven patients treated with investigational base-editing therapy BEAM-101 demonstrated robust and durable increases in fetal hemoglobin (HbF) and reductions in sickle hemoglobin (HbS), rapid neutrophil and platelet engraftment, and normalized or improved markers of hemolysis.
No VOCs were reported post-engraftment.
Key highlights include the following:
<ul>
<li>Rapid and Sustained Increases in Protective Fetal Hemoglobin (HbF): All patients achieved endogenous HbF levels exceeding 60% and reduction in corresponding sickle hemoglobin (HbS) below 40% that was durable. A pancellular distribution of HbF was observed after the elimination of transfused blood.</li>
<li>Robust and Sustained Total Hemoglobin (Hb) Levels: Total hemoglobin levels increased rapidly with a resolution of anemia in patients after the elimination of the transfused blood.</li>
<li>Normalization of Hemolysis Markers: Key markers of hemolysis, including indirect bilirubin, haptoglobin, lactate dehydrogenase and reticulocytes, normalized or improved in all patients following BEAM-101 treatment.</li>
<li>Safety Profile Consistent with Busulfan and Autologous Hematopoietic Stem Cell Transplantation.</li>
</ul>
In November, the company said that one patient died due to respiratory failure likely related to busulfan conditioning four months after BEAM-101 infusion. However, the investigator determined that the death was <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41756981/gene-therapy-developer-beam-therapeutics-reports-one-patient-death-in-early-stage-sickle-cell-dis" rel="noreferrer noopener">unrelated to BEAM-101</a>.
On Sunday, Beam Therapeutics announced new data for its Engineered Stem Cell Antibody Evasion (ESCAPE) conditioning platform, which was presented at the American Society of Hematology Annual <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42380675/beam-therapeutics-presents-new-non-human-primate-nhp-data-demonstrating-proof-of-concept-for-escap" rel="noreferrer noopener">Meeting and Exposition</a>.
ESCAPE comprises two investigational drug products, BEAM-103 and BEAM-104. The company intends to advance BEAM-103 and BEAM-104 for development in sickle cell disease and beta-thalassemia.
In the preclinical study, administration of the BEAM-104 edited cells to antibody-conditioned animals led to long-term engraftment.
Dosing with the BEAM-103 mAb led to rapid and near complete replacement of wild-type erythroid cells by edited cells, leading to early induction of therapeutically relevant levels of HbF.
BEAM-103 dosing was well tolerated, with no need for transfusions, antibiotics, or additional supportive care.
William Blair writes, &#8220;While the patient death is unfortunate, we see the event as highlighting the need for less-toxic preconditioning options, and we think Beam is leading the space in this regard.&#8221;
Price Action: At last check on Monday, BEAM stock was up 0.52% at $26.89.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42387962/palantir-scores-368-million-deal-with-ussocom-to-lead-ai-powered-mission-command" target="_blank" rel="noreferrer noopener">Palantir Jumps After Securing USSOCOM Contract Boost &#8211; What&#8217;s Going On?</a></li>
</ul>

Analyst Color

General

Beam Therapeutics Unveils New Safety, Efficacy Data From Sickle Cell Disease Candidate, Stock Gains

<ul>
<li>NHP Data Showed CD117 Monoclonal Antibody (mAb) Conditioning Successfully Achieved Long-term Engraftment of Base-edited Hematopoietic Stem Cells and Induced Robust Levels of&nbsp;Hemoglobin F</li>
<li>mAb Dosing Well Tolerated Without Need for Supportive Care</li>
<li>Beam on Track to Initiate Phase 1-enabling Studies by End of 2024</li>
</ul>

Reported Sunday, Beam Therapeutics Showcases Proof-Of-Concept Non-Human Primate Data For ESCAPE, A Non-Genotoxic Antibody-Based Conditioning Strategy For Sickle Cell Disease, At ASH 2024

<a href="https://www.globenewswire.com/Tracker?data=iLZ9x69dnGVH2dDnn_bqKdcRxuqSk8c9oR7gIU98LWWR7EKFfy8SYnFEVh3zx6Q_3ZtiiGoWRO5HH5TVXoK6RKufAiNiO3mNqfmZfC89hSY=">Beam Therapeutics Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>), a biotechnology company developing precision genetic medicines through base editing, today announced new safety and efficacy data from its BEACON Phase 1/2 clinical trial of BEAM-101 in patients with sickle cell disease (SCD) with severe vaso-occlusive crises (VOCs). The data were featured today in the press program for the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego and will be presented in an oral session on Sunday, Dec. 8, 2024, at 10 a.m. PT.
All Seven Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of &gt;60%, Hemoglobin S (HbS) Reduction to &lt;40%, and Resolution of Anemia Post-BEAM-101 Treatment
Initial Safety Profile Consistent with Busulfan Conditioning and Autologous Hematopoietic Stem Cell Transplantation
All Seven Patients Dosed Achieved Target Cell Dose with One or Two Mobilization Cycles and Experienced Rapid Neutrophil and Platelet Engraftment
Markers of Hemolysis Normalized or Improved in All Patients

Beam Therapeutics Announced New Data from BEACON Phase 1/2 Clinical Trial Of BEAM-101 In Sickle Cell Disease at ASH Meeting; Said All Seven Patients Treated With BEAM-101 Achieved Hemoglobin F (HbF) Induction Of >60%, Hemoglobin S (HbS) Reduction To <40%, And Resolution Of Anemia Post-BEAM-101 Treatment

WIIM

Beam Therapeutics shares are trading higher. The company appointed a new CFO.

Management

Beam Therapeutics Has Appointed Sravan Emany As Chief Financial Officer, Effective December 19

Cathie Wood, CEO of ARK Invest, is doubling down on biologics, seeing unprecedented potential at the intersection of artificial intelligence, genetic sequencing, and gene editing technologies.
What Happened: Wood&#8217;s enthusiasm centers on what she describes as a transformative convergence of technologies that could revolutionize medical treatment and drug discovery. 
Speaking candidly about the sector, Wood highlighted the remarkable progress in genetic therapies, particularly in companies like Crispr Therapeutics AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>), Intellia Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>), and Beam Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>).
Her most striking example involves Crispr Therapeutics&#8217; recent breakthrough in sickle cell disease treatment. Wood noted, referencing how patients who previously required 12 to 20 annual blood transfusions might now be free from such interventions.
The strategy extends beyond treatment breakthroughs to drug development itself. Wood points to companies like Recursion Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) as leveraging artificial intelligence to dramatically reduce clinical trial failure rates and accelerate drug development timelines.
However, the market performance of these innovative companies tells a more nuanced story. Year-to-date, the stocks have experienced significant volatility: Crispr Therapeutics is down 25.36%, Intellia Therapeutics has dropped 52.21%, Beam Therapeutics declined 3.04%, and Recursion Pharmaceuticals fell 9.80%, according to <a href="https://www.benzinga.com/pro/">data from Benzinga Pro</a>.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Which market sector excites <a href="https://twitter.com/CathieDWood?ref_src=twsrc%5Etfw">@CathieDWood</a> the most and why? In <a href="https://twitter.com/hashtag/askARK?src=hash&amp;ref_src=twsrc%5Etfw">#askARK</a>, she shares her growing enthusiasm for the biologics space. Have more questions for Cathie? Share them in the comments. <a href="https://t.co/WjilZChce6">pic.twitter.com/WjilZChce6</a>
&mdash; ARK Invest (@ARKInvest) <a href="https://twitter.com/ARKInvest/status/1861431767506268404?ref_src=twsrc%5Etfw">November 26, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/general/entertainment/24/11/42205763/disney-reaches-43m-settlement-in-gender-pay-discrimination-lawsuit-women-can-expect-equitable-treatment-moving-forward">Disney Reaches $43M Settlement In Gender Pay Discrimination Lawsuit: &#8216;Women Can Expect Equitable Treatment&#8217; Moving Forward</a>
Why It Matters: ARK&#8217;s commitment to this sector is evident through its Genomic Revolution ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>), which manages net assets of $1.179 billion. The fund&#8217;s performance reflects the sector&#8217;s volatility, with annual returns ranging from a high of 180.50% in 2020 to a low of -53.94% in 2022.
The ETF&#8217;s current top holdings underscore Wood&#8217;s strategic focus on innovative biological technologies. Twist Bioscience Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>) leads the portfolio at 8.90%, followed by Crispr Therapeutics at 7.88% and Recursion Pharmaceuticals at 6.17%. Other significant investments include CareDx Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>), Veracyte Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>), and Adaptive Biotechnologies Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>), representing a diversified approach to genomic and biological innovation.
Wood&#8217;s vision suggests a potential $400 billion market opportunity in biologics over the next five years, driven by the unprecedented convergence of AI, sequencing technologies, and gene editing. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42202496/goldman-sachs-expects-major-selloffs-in-canadian-dollar-mexican-peso-says-trump-tariffs-threaten-usmca-agreement">Goldman Sachs Expects Major Selloffs In Canadian Dollar, Mexican Peso, Says Trump Tariffs Threaten USMCA Agreement</a></li>
</ul>
Image via Ark Invest
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?

BofA Securities downgraded Editas Medicine Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>), citing few value-driving catalysts <a target="_blank" href="https://www.benzinga.com/quote/EDIT/analyst-ratings" rel="noreferrer noopener">in the near term</a>.
In its third-quarter earnings release, Editas Medicine said it engaged an investment bank to lead the process of partnering or out-licensing reni-cel (renizgamglogene autogedtemcel, previously EDIT-301).
The company is developing reni-cel for sickle cell disease and transfusion-<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41710488/editas-medicine-announces-third-quarter-2024-results-and-business-updates" rel="noreferrer noopener">dependent Beta Thalassemia</a>.
The company is on track to share additional clinical and patient-reported outcomes data from 28 patients in the RUBY trial for sickle cell disease at the American Society of Hematology Annual Meeting in December.
The company has completed enrollment of the adult cohort of the EdiTHAL trial for thalassemia and continues patient dosing.
The analyst notes that Editas announced a shift in focus toward in vivo development, specifically working on lipid nanoparticle (LNP) formulations for treating sickle cell disease (SCD) and thalassemia.
While preclinical data shows some progress—29% editing in hematopoietic stem and progenitor cells (HSPCs) and around 20% of red blood cells expressing fetal hemoglobin (HbF)—more evidence is needed to prove functional benefits and advance to clinical trials.
Meanwhile, competitors like Beam Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) and CRISPR Therapeutics AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>) are investing heavily in their in vivo programs for SCD and thalassemia, with better-prepared manufacturing and development for clinical trials.
Given the deprioritization of reni-cel and the increasingly competitive environment for ex vivo therapies, BofA has reduced estimates and probabilities of success in SCD and beta-thal to 10% (from 60% prior).
The analyst downgraded from Buy to Underperform, with a price target of $1, down from $13.
This intensifying competition, limited short-term clinical milestones, and declining interest in gene editing pose challenges for Editas and could pressure its stock in the near term.
Price Action: EDIT stock is down 0.41% at $2.43 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/media/24/11/42168509/amd-teams-up-with-taiwan-semi-to-take-on-samsung-in-smartphone-market" target="_blank" rel="noreferrer noopener">AMD Teams Up With Taiwan Semi To Take On Samsung In Smartphone Market</a></li>
</ul>
Photo by Ground Picture on Shutterstock.

Downgrades

EDIT

Editas Medicine Downgraded: Analyst Sees Limited Near-Term Catalysts

RBC Capital analyst Luca Issi maintains Beam Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) with a Sector Perform and lowers the price target from $27 to $24.

RBC Capital Maintains Sector Perform on Beam Therapeutics, Lowers Price Target to $24

Beam Therapeutics shares are trading higher after Leerrink Partners upgraded the stock from Market Perform to Outperform and raised its price target from $27 to $39.

Press Releases

Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ASH) Annual Meeting

Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference

Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader

Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting

Beam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts

Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR

Comments

Beam Therapeutics

뉴스

파트너 / 기고자

벤징가 글로벌